These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 6430321)

  • 21. [Metabolites of cyclandelate. Vasodilator action and inhibition of phosphodiesterase by metabolites of cyclandelate].
    Himber J; De Burlet G; Andermann G
    Ann Pharm Fr; 1987; 45(3):233-41. PubMed ID: 3434974
    [No Abstract]   [Full Text] [Related]  

  • 22. High-performance liquid chromatographic method for the determination of a cyclandelate metabolite, mandelic acid, in human plasma.
    Kojima K; Uezono Y; Takahashi T; Nakanishi Y
    J Chromatogr; 1988 Mar; 425(1):203-7. PubMed ID: 3360871
    [No Abstract]   [Full Text] [Related]  

  • 23. Inhibition of atherosclerosis in the rabbit by cyclandelate.
    Middleton A; Edwards E; White DA; Middleton B
    Br J Clin Pract Suppl; 1984; 34():39-42. PubMed ID: 6430322
    [No Abstract]   [Full Text] [Related]  

  • 24. Letter: Cyclandelate and improved brain function.
    Wechsler AF
    Am J Psychiatry; 1974 Jun; 131(6):723. PubMed ID: 4827806
    [No Abstract]   [Full Text] [Related]  

  • 25. Determination of plasma concentrations of cyclandelate and mandelic acid in patients with generalized atherosclerotic vasculopathy treated with oral cyclandelate.
    Forconi S; Cappelli R; Guerrini M; Volpi L; Frigerio C; Di Perri T
    J Int Med Res; 1990; 18(4):266-72. PubMed ID: 2227073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Evidence of a pharmacokinetic-pharmacodynamic relationship between pharmaco-EEG in healthy subjects after administration of cyclandelate].
    Dimpfel W; Schober F; Wedekind W; Kleinbloesem C; Coors C
    Arzneimittelforschung; 1994 Sep; 44(9):999-1004. PubMed ID: 7986255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Stability of cyclandelate in a soft capsule].
    Richard J; Andermann G
    Pharm Acta Helv; 1982; 57(4):116-21. PubMed ID: 7089017
    [No Abstract]   [Full Text] [Related]  

  • 28. Chronic cerebrovascular disorders: a clinical study with cyclandelate.
    Bassi S; Albizzati MG; Sbacchi M; Frattola L
    Br J Clin Pract; 1984 Oct; 38(10):344-9. PubMed ID: 6498057
    [No Abstract]   [Full Text] [Related]  

  • 29. Electroencephalographic study of dose-response relations for cyclandelate on hyperventilation-induced vasospasm in human brain.
    Korenyi C; Whittier JR
    Angiology; 1969 Oct; 20(9):529-34. PubMed ID: 5824354
    [No Abstract]   [Full Text] [Related]  

  • 30. Effects of cyclandelate on diabetic peripheral neuropathy.
    Canal N; Comi G; Marchettini P; Pozza G
    Br J Clin Pract Suppl; 1984; 34():62-8. PubMed ID: 6430326
    [No Abstract]   [Full Text] [Related]  

  • 31. Simultaneous determination of cyclandelate and its metabolite in human plasma by capillary column gas-liquid chromatography.
    Andermann G; Dietz M
    J Chromatogr; 1981 May; 223(2):365-70. PubMed ID: 7251791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The anti-hypoxaemic effect of cyclandelate in man measured in human volunteers using computer-assisted oculodynamic methodology.
    Schaffler K
    Br J Clin Pract Suppl; 1984; 34():51-7. PubMed ID: 6430324
    [No Abstract]   [Full Text] [Related]  

  • 33. [Study of the bioavailability of drugs with a cyclandelate base].
    Andermann G; Dietz M; Mergel D
    Pharm Acta Helv; 1979; 54(12):366-9. PubMed ID: 583451
    [No Abstract]   [Full Text] [Related]  

  • 34. [New determination of cyclandelate in plasma (author's transl)].
    Andermann G; Dietz M; Mergel D
    J Pharm Belg; 1979; 34(4):233-7. PubMed ID: 501515
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of cyclandelate on dementia.
    Westreich G; Alter M; Lundgren S
    Stroke; 1975; 6(5):535-8. PubMed ID: 1101457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy of an etofylline-cyclandelate combination in age-dependent cerebrovascular insufficiency].
    Foltyn P; Lücker PW; Schnitker J
    Arzneimittelforschung; 1982; 32(10):1322-8. PubMed ID: 6891235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specific effects of cyclandelate on memory.
    Ananth J
    Drugs; 1987; 33 Suppl 2():97-102. PubMed ID: 3622311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigation on spasmolytics. VII. The metabolism of 3,5,5-trimethylcyclohexylmandelate (cyclandelate). II.
    ERNSTING MJ; REKKER RF; TERSTEEGE HM; NAUTA WT
    Arzneimittelforschung; 1962 Jun; 12():632-5. PubMed ID: 13890671
    [No Abstract]   [Full Text] [Related]  

  • 39. Multifocal infarct dementia treated by cyclandelate and monitored by quantitative EEG.
    Harding GF; Hall P; Young J; Smith GA
    Angiology; 1978 Feb; 29(2):139-40. PubMed ID: 347986
    [No Abstract]   [Full Text] [Related]  

  • 40. Investigation on spasmolytics. VIII. The metabolism of 3,5,5-trimethylcyclohexyl mandelate (Cyclandelate) (III).
    ERNSTING MJ; REKKER RF; TERSTEEGE HM; NAUTA WT
    Arzneimittelforschung; 1962 Jul; 12():691-4. PubMed ID: 13890672
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.